Osmetech Licenses Roche Hot Start(R) Polymerase Technology

| From

PASADENA, Calif. - June 5 (SEND2PRESS NEWSWIRE) -- Osmetech plc (AIM; LSE) today announced that it has been granted a non-exclusive worldwide diagnostics license from Swiss-based F. Hoffman LaRoche Ltd and its US affiliate Roche Molecular Systems Inc. (collectively "Roche") to use Hot Start(R) polymerase technology in Osmetech nucleic acid diagnostic assays.

(c) Send2PressThis license allows Osmetech to include Hot Start(R) polymerase as part of the diagnostic kit providing Osmetech customers with a cost savings and level of convenience, and demonstrates Osmetech's diagnostic commitment of including everything in a kit rather than having the customer source and license components from various vendors.

This latest license complements our highly sensitive electrochemical detection platform that is backed by an extensive patent portfolio, says Osmetech CEO James White. "We have over 145 granted patents worldwide,and several key in-licenses, built on acquisitions and collaborations with the likes of Harvard University, California Institute of Technology (Caltech), Motorola, Clinical Micro Sensors, Inc., University of North Carolina, Concordia University, Johns Hopkins University, University of Michigan, University of Washington, and Epidauros. This agreement with Roche will provide an added benefit for our customers who will not be required to obtain this license from Roche and pay Hot Start(R) polymerase royalties on tests performed when using Osmetech products."

In 2006 Osmetech launched the eSensor(R) platform, an FDA cleared electrochemistry-based array system for cystic fibrosis carrier detection, and is currently in the process of completing its next generation instrument, the eSensor(R) XT8. Osmetech plans to seek FDA approval for and launch of this instrument with a CYP450/VKOR, a test to determine a patient's response to warfarin, later this year. The CYP450/VKOR assay is the first of many pharmacogenomic assays planned for the system, which is designed to meet the needs of the rapidly expanding field of personalized medicine.

About Osmetech
Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international molecular diagnostics business with operations in Boston and Pasadena in the US, serving the high growth, near patient testing market targeting small to medium sized hospitals. Osmetech has launched eSensor(R), an FDA cleared electrochemistry-based array system, for cystic fibrosis carrier detection and plan to launch a number of pharmacogenomic assays utilizing the same proprietary technology.

More information:

Ticker: AIM LSE: OMH (London Stock Exchange)

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   STUMBLE   LinkedIn   Instapaper   Buffer

The content of the above press release was provided by the “news source” (Osmetech plc) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2007 Osmetech plc with newswire version Copr. © 2007 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Oct 25 2016:
[ count retired 8.4.16 ]

or: Search

back to top
REFERENCES: eSensor platform, Osmetech plc, Osmetech plc, Molecular Diagnostics, eSensor platform, diagnostics license, F. Hoffman LaRoche Ltd, Roche Molecular Systems Inc., Hot Start polymerase technology, nucleic acid diagnostic assays, eSensor XT8, response to warfarin, AIM LSE: OMH, news, press release from Osmetech plc, Jun 5, 2007, Devices and Research, , , , , Osmetech Licenses Roche Hot Start(R) Polymerase Technology